undamentalytics Newsletter
Sign in

Innoviva, Inc. income statement

In fiscal 2025, Innoviva, Inc. reported revenue of $411m, up 14.7% on the year before, operating income of $164m (a 39.8% margin) and net income of $271m, or $3.30 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue24242565854134217261261337392331310359411440
Gross profit——————————————246296308318
Research and development787510489731100214134143129
Selling, general and administrative——313148——————14166498116113126
General and administrative2727———352023322015———————
Operating income−81−78−110−25−29−3432109184238246321375—114167164163
Interest expense6666937525244241918191619221718
Income before tax————−31−74−196013421023335444528719437327419
Income tax——0000000−1964260766714145662
Net income−85−84−115−19−171−168−196013439515722426621418023271357
Diluted EPS−$1.35−$1.16−$1.41−$0.20−$1.67−$1.50−$0.16$0.53$1.17$3.53$1.43$2.02$2.87$2.37$2.20$0.36$3.30$4.08
Diluted shares (average)63m72m82m91m102m112m115m123m120m113m113m114m94m95m87m74m85m88m
EBITDA−76−72−102−22−25−2246123198252260335389—————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: INVA vs IRWDINVA vs XERSALVO vs INVA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Innoviva, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innoviva, Inc.